PROMACTA is a thrombopoietin receptor agonist indicated:
• for the treatment of thrombocytopenia in adult and pediatric patients
1 year and older with persistent or chronic immune thrombocytopenia
(ITP) who have had an insufficient response to corticosteroids,
immunoglobulins, or splenectomy. PROMACTA should be used only in
patients with ITP whose degree of thrombocytopenia and clinical
condition increase the risk for bleeding.
• for the treatment of thrombocytopenia in patients with chronic hepatitis
C to allow the initiation and maintenance of interferon-based therapy.
PROMACTA should be used only in patients with chronic hepatitis C
whose degree of thrombocytopenia prevents the initiation of interferonbased
therapy or limits the ability to maintain interferon-based therapy.
• in combination with standard immunosuppressive therapy for the firstline
treatment of adult and pediatric patients 2 years and older with
severe aplastic anemia.
• for the treatment of patients with severe aplastic anemia who have had an
insufficient response to immunosuppressive therapy.
